Advertisement

International Journal of Clinical Pharmacy

, Volume 40, Issue 2, pp 458–463 | Cite as

Patient satisfaction with a chronic kidney disease risk assessment service in community pharmacies

  • Pankti A. GheewalaEmail author
  • Gregory M. Peterson
  • Syed Tabish R. Zaidi
  • Matthew D. Jose
  • Ronald L. Castelino
Research Article
  • 172 Downloads

Abstract

Background

Patient satisfaction is an important determinant of the feasibility and sustainability of community pharmacy screening services. However, few studies have evaluated this, with no such study performed for a chronic kidney disease risk assessment service.

Objective

The aim was to determine patient satisfaction with a chronic kidney disease risk assessment service performed in community pharmacies.

Setting

Community pharmacies in the state of Tasmania, Australia.

Method

An anonymous nine-item satisfaction survey, with Likert-type scales, was developed following a literature review of existing surveys. Reliability of the nine-item scale was determined using Cronbach’s alpha. Patients were asked an additional question on willingness to pay, with choices of amount from $5 to $25. The satisfaction survey was mailed to 389 patients who participated in the chronic kidney disease risk assessment study.

Main outcome measure

Patient level of satisfaction with and willingness to pay for the chronic kidney disease service.

Results

Responses from 143 participants were included in the final analysis. Cronbach’s alpha for the nine-item satisfaction scale was 0.87. The majority of participants agreed that the time required to undergo the risk assessment process was justified (90.2%); overall, they were satisfied with the chronic kidney disease risk assessment service (90.0%) and they felt comfortable with the pharmacist referring their results to their doctor (88.9%). Of 136 participants who answered the question on willingness to pay, 62.9% indicated that they would pay for the chronic kidney disease service. Of these, 29.2, 25.8 and 19.1% were willing to pay $20, $10 and $5, respectively.

Conclusion

Patient satisfaction with the community pharmacy-based chronic kidney disease risk assessment was high. These findings provide support for the implementation of the service within community pharmacy practice.

Keywords

Australia Chronic kidney disease Community pharmacy Patient satisfaction Questionnaire Risk assessment 

Notes

Acknowledgements

We would like to acknowledge all participants for their contribution to research by participating in this study.

Funding

This study was funded by the Tasmanian Community Fund and supported by the Division of Pharmacy, School of Medicine, Faculty of Health, University of Tasmania.

Conflicts of interest

All the authors declare that they have no conflict of interest.

Supplementary material

11096_2018_603_MOESM1_ESM.docx (21 kb)
Supplementary material 1 (DOCX 20 kb)

References

  1. 1.
    Thoopputra T, Pongmesa T, Newby DA, Schneider J, Li SC. Opportunistic risk screening for type 2 diabetes: exploring of application of diabetes risk assessment tool in community pharmacy in Australia and Thailand. Value Health Reg Issues. 2016;9(Supplement C):1–7.PubMedGoogle Scholar
  2. 2.
    Peterson GM, Fitzmaurice KD, Kruup H, Jackson SL, Rasiah RL. Cardiovascular risk screening program in Australian community pharmacies. Pharm World Sci. 2010;32(3):373–80.CrossRefPubMedGoogle Scholar
  3. 3.
    Goode JV, Swiger K, Bluml BM. Regional osteoporosis screening, referral, and monitoring program in community pharmacies: findings from Project ImPACT: osteoporosis. J Am Pharm Assoc (2003). 2004;44(2):152–60.CrossRefGoogle Scholar
  4. 4.
    Lowres N, Neubeck L, Salkeld G, Krass I, McLachlan AJ, Redfern J, et al. Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study. Thromb Haemost. 2014;111(6):1167–76.CrossRefPubMedGoogle Scholar
  5. 5.
    Krass I, Mitchell B, Clarke P, Brillant M, Dienaar R, Hughes J, et al. Pharmacy diabetes care program: analysis of two screening methods for undiagnosed type 2 diabetes in Australian community pharmacy. Diabetes Res Clin Pract. 2007;75(3):339–47.CrossRefPubMedGoogle Scholar
  6. 6.
    Gudka S, Marshall L, Creagh A, Clifford RM. To develop and measure the effectiveness and acceptability of a pharmacy-based chlamydia screening intervention in Australia. BMJ Open. 2013;3(8):e003338.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Cerulli J, Zeolla MM. Impact and feasibility of a community pharmacy bone mineral density screening and education program. J Am Pharm Assoc (2003). 2004;44(2):161–7.CrossRefGoogle Scholar
  8. 8.
    Hersberger KE, Renggli VP, Nirkko AC, Mathis J, Schwegler K, Bloch KE. Screening for sleep disorders in community pharmacies—evaluation of a campaign in Switzerland. J Clin Pharm Ther. 2006;31(1):35–41.CrossRefPubMedGoogle Scholar
  9. 9.
    Breslow RM. Patient attitudes regarding pharmacist-administered memory screening in community pharmacies. J Am Pharm Assoc (2033). 2013;53(6):648–51.CrossRefGoogle Scholar
  10. 10.
    Naik Panvelkar P, Saini B, Armour C. Measurement of patient satisfaction with community pharmacy services: a review. Pharm World Sci. 2009;31(5):525–37.CrossRefPubMedGoogle Scholar
  11. 11.
    MacKeigan LD, Larson LN. Development and validation of an instrument to measure patient satisfaction with pharmacy services. Med Care. 1989;27(5):522–36.CrossRefPubMedGoogle Scholar
  12. 12.
    Australian Bureau of Statistics. Australian Health Survey: Biomedical results for Chronic Diseases, 2011–2012. 2013. http://www.abs.gov.au/websitedbs/D3310114.nsf/home/home?opendocument#from-banner=GT. 1 Aug 2017.
  13. 13.
    Mathew T, Corso O. Review article: Early detection of chronic kidney disease in Australia: which way to go? Nephrology (Carlton, VIC). 2009;14(4):367–73.CrossRefGoogle Scholar
  14. 14.
    Johnson DW, Atai E, Chan M, Phoon RK, Scott C, Toussaint ND, et al. KHA-CARI guideline: Early chronic kidney disease: detection, prevention and management. Nephrology (Carlton, VIC). 2013;18(5):340–50.CrossRefGoogle Scholar
  15. 15.
    Smart NA, Titus TT. Outcomes of early versus late nephrology referral in chronic kidney disease: a systematic review. Am J Med. 2011;124(11):1073–80.CrossRefPubMedGoogle Scholar
  16. 16.
    Gheewala PA, Peterson GM, Zaidi ST, Bereznicki L, Jose MD, Castelino RL. A web-based training program to support chronic kidney disease screening by community pharmacists. Int J Clin Pharm. 2016;38(5):1080–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Hippisley-Cox J, Coupland C. Predicting the risk of chronic Kidney Disease in men and women in England and Wales: prospective derivation and external validation of the QKidney Scores. BMC Fam Pract. 2010;11(1):49.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Krass I, Delaney C, Glaubitz S, Kanjanarach T. Measuring patient satisfaction with diabetes disease state management services in community pharmacy. Res Social Adm Pharm. 2009;5(1):31–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Butler KT, Ruisinger JF, Bates J, Prohaska ES, Melton BL. Participant satisfaction with a community-based medication synchronization program. J Am Pharm Assoc (2003). 2015;55(5):534–9.CrossRefGoogle Scholar
  20. 20.
    Tinelli M, Blenkinsopp A, Bond C. Development, validation and application of a patient satisfaction scale for a community pharmacy medicines-management service. Int J Pharm Pract. 2011;19(3):144–55.CrossRefPubMedGoogle Scholar
  21. 21.
    Paddock LE, Veloski J, Chatterton ML, Gevirtz FO, Nash DB. Development and validation of a questionnaire to evaluate patient satisfaction with diabetes disease management. Diabetes Care. 2000;23(7):951–6.CrossRefPubMedGoogle Scholar
  22. 22.
    Toh LS, Lai PSM, Wu DB-C, Wong KT, Low BY, Tan ATB, et al. The development and validation of the Satisfaction Questionnaire for Osteoporosis Prevention in Malaysia. Patient Prefer Adherence. 2014;8:1365–81.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Suh DC. Consumers’ willingness to pay for pharmacy services that reduce risk of medication-related problems. J Am Pharm Assoc (Wash). 2000;40(6):818–27.CrossRefGoogle Scholar
  24. 24.
    Daftary MN, Lee E, Dutta AP, Olagundoye A, Xue Z. Patients’ willingness to pay for cognitive pharmacy services in ambulatory care settings in the USA. J Pharm Pract Res. 2003;33(4):265–7.CrossRefGoogle Scholar
  25. 25.
    Barner JC, Branvold A. Patients’ willingness to pay for pharmacist-provided menopause and hormone replacement therapy consultations. Res Social Adm Pharm. 2005;1(1):77–100.CrossRefPubMedGoogle Scholar
  26. 26.
    Benrimoj SI, Frommer MS. Community pharmacy in Australia. Aust Health Rev. 2004;28(2):238–46.CrossRefPubMedGoogle Scholar
  27. 27.
    Eades CE, Ferguson JS, O’Carroll RE. Public health in community pharmacy: a systematic review of pharmacist and consumer views. BMC Public Health. 2011;11(1):582.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Lowres N, Krass I, Neubeck L, Redfern J, McLachlan AJ, Bennett AA, et al. Atrial fibrillation screening in pharmacies using an iPhone ECG: a qualitative review of implementation. Int J Clin Pharm. 2015;37(6):1111–20.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Pankti A. Gheewala
    • 1
    Email author
  • Gregory M. Peterson
    • 1
  • Syed Tabish R. Zaidi
    • 1
  • Matthew D. Jose
    • 2
  • Ronald L. Castelino
    • 3
  1. 1.Division of Pharmacy, School of Medicine, Faculty of HealthUniversity of TasmaniaHobartAustralia
  2. 2.School of Medicine, Faculty of HealthUniversity of TasmaniaHobartAustralia
  3. 3.Sydney Nursing SchoolThe University of SydneyCamperdownAustralia

Personalised recommendations